This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
August 11, 2017
Notice of Nexstim Plc’s Half-Yearly Report H1 2017
August 10, 2017
Strongbridge Biopharma plc to Present at the Canaccord Genuity 37th Annual Growth Conference
August 10, 2017
Nordic Nanovector to Present at Wedbush PacGrow Healthcare Conference
August 10, 2017
Altimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update
August 07, 2017
Strongbridge Biopharma plc Provides Updates on KEVEYIS® Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results
August 02, 2017
Aprea Therapeutics Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Platinum-Resistant High-Grade Serous Ovarian Cancer
August 02, 2017
Zubsolv® gains preferred position on CVS Caremark 2018 formulary
August 01, 2017
GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of LHON
July 31, 2017
Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma
July 28, 2017
GenSight Biologics Reports Interim Financial Results for the First Half of 2017